View metadata, citation and similar papers at core.ac.uk
brought to you by CORE
provided by SZTE Publicatio Repozitórium - SZTE - Repository of Publications

Brain Recovery Review Series *J. Cell. Mol. Med. Vol 15, No 4, 2011 pp. 701-717*

Guest Editor: D.F. Mureşanu

Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines

Dénes Zádori [a], Péter Klivényi [a], Imola Plangár [a], József Toldi [b], László Vécsei [a, *]

[a] *Department of Neurology, Albert Szent-Györgyi Clinical Centre, University of Szeged, Szeged, Hungary*
[b] *Department of Physiology, Anatomy and Neuroscience, University of Szeged, Szeged, Hungary*

Received: September 3, 2010; Accepted: December 8, 2010

Abstract

Parkinson's disease (PD) and Huntington's disease (HD) are progressive chronic neurodegenerative disorders that are accompanied by a considerable impairment of the motor functions. PD may develop for familial or sporadic reasons, whereas HD is based on a definite genetic mutation. Nevertheless, the pathological processes involve oxidative stress and glutamate excitotoxicity in both cases. A number of metabolic routes are affected in these disorders. The decrease in antioxidant capacity and alterations in the kynurenine pathway, the main pathway of the tryptophan metabolism, are features that deserve particular interest, because the changes in levels of neuroactive kynurenine pathway compounds appear to be strongly related to the oxidative stress and glutamate excitotoxicity involved in the disease pathogenesis. Increase of the antioxidant capacity and pharmacological manipulation of the kynurenine pathway are therefore promising therapeutic targets in these devastating disorders.

Keywords: neurodegeneration • Parkinson's disease • Huntington's disease • kynurenine pathway • kynurenic acid • quinolinic acid • oxidative stress • glutamate excitotoxicity • neuroprotection

Introduction

Parkinson's disease (PD) is a chronic progressive neurodegenerative disorder [1] that exhibits increasing prevalence with aging. On average, it affects about 2 in 1000 people [2–4]. Only about 10% of the cases reveal a familial background; the remaining 90% are considered to be sporadic with uncertain aetiology, which draws attention to the role of possible environmental risk factors

*Correspondence to: László VÉCSEI, MD, Ph.D., D.Sc.,
Department of Neurology, Albert Szent-Györgyi Clinical Centre,
University of Szeged, Semmelweis u. 6, H-6725 Szeged, Hungary.
Tel.: +36 62 545348
Fax: +36 62 545597
E-mail: vecsei@nepsy.szote.u-szeged.hu

doi:10.1111/j.1582-4934.2010.01237.x

© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd

(reviewed in [5]). The main clinical features of PD, including resting tremor, rigidity, brady- and hypokinesia and postural instability, develop in consequence of the complex dysfunction of the motor network, with crucial roles for the alterations in the basal ganglia circuits (reviewed in [6]). The main underlying pathological hallmark is a preferential loss of brain stem catecholaminergic, and especially mesencephalic dopaminergic neurons in the substantia nigra pars compacta (SNpc) and the development of intracellular inclusions called Lewy bodies [7]. The resulting dopamine deficiency, apparent mainly in the striatum, means that the brain is no longer capable of sufficient motor function control (reviewed in [6]).

Huntington's disease (HD) is likewise a chronic progressive neurodegenerative disease [8], observed in the middle-aged. In contrast with PD, it is genetically determined by an autosomal dominantly inherited definite single mutation in the IT15 gene coding for the huntingtin protein [9]. The prevalence of HD is rather low relative to that of PD; it affects only about 5 in 100,000 people [10–13]. The clinical features of HD are characterized by cognitive, psychiatric and motor symptoms (reviewed in [14, 15]). In view of the motor symptoms, the typical loss of coordination of the voluntary movements and the appearance of involuntary movements (such as chorea and dystonia) evolve. Further, a progressive gait impairment also develops, manifested in brady- and hypokinesia [16, 17]. The pathological alterations are mainly seen in the central nervous system (CNS), and especially in the caudate nucleus, the putamen and the deeper layers of the cerebral cortex [18]. The loss of γ-aminobutyric acidergic (GABAergic) medium-sized spiny neurons (MSNs) in the striatum (caudate nucleus + putamen) is the most pronounced feature [19–21], resulting in a dysfunction of the basal ganglia circuits, and leading to the development of the characteristic symptoms (reviewed in [22]).

The role of mitochondrial impairment and oxidative stress in neurodegeneration

Background

The mitochondria take part in both physiological and pathological processes, such as energy supply, signalling, Ca^{2+}-homeostasis, cell cycle regulation, apoptosis, free radical generation, thermogenesis, development and aging (reviewed in [23, 24]; Fig. 1). The electrons arising from the oxidation of the reduced coenzymes nicotinamide adenine dinucleotide (NAD^+) and flavin adenine dinucleotide reduce molecular oxygen (O_2) predominantly to H_2O, but 1–2% of the O_2 is incompletely reduced, producing the superoxide anion ($O_2^{\cdot -}$). In the event of the dysfunction of one or more respiratory chain complexes, the production of $O_2^{\cdot -}$ is enhanced. Although $O_2^{\cdot -}$ itself is only moderately damaging, it is highly reactive [25]. It can be transformed to hydrogen peroxide (H_2O_2), a process catalysed by manganese superoxide dismutase, or it can interact with nitric oxide, providing the highly toxic peroxynitrite anion. Under physiological conditions, H_2O_2 is broken down by glutathione peroxidase or catalase, but if H_2O_2 is present in excess amount, it can react with transition metal ions (*e.g.* Fe^{2+}) in the Fenton reaction, producing another highly toxic and reactive metabolite, the hydroxyl radical. Besides the mitochondria (the electron transport chain; ETC) as a major source of free radicals, other free radical-producing pathways involve participation of the enzymes xanthine oxidase, monoamine oxidase, cytochrome P450, myeloperoxidase, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, etc. In contrast with other organs, the brain is more sensitive to lesion-provoking reactive oxygen species because its O_2 demand is high, it contains high concentrations of polyunsaturated lipids and its antioxidant capacity is relatively low (reviewed in [26]). There is evidence that the mitochondria play important roles in both necrotic and apoptotic cell death (reviewed in [27, 28]). It is important that the occurrence of necrosis or apoptosis depends on the severity of the pathological stimuli [29, 30]. These stimuli, such as oxidative stress, a Ca^{2+} overload, or ATP depletion, can lead to the formation of mitochondrial permeability transition (MPT) pores, a process strongly influenced by the Bcl-2 family proteins (reviewed in [31]). The presence of these pores allows the release of cytochrome-c into the cytosol, where it forms an essential part of the apoptosome, which is composed of cytochrome-c, apoptotic protease activating factor 1 and procaspase 9 [32]. The result is the activation of caspase-9, which then processes and activates other caspases, leading to the biochemical execution of the cells. It should be mentioned that caspase-independent cell death pathways also exist (reviewed in [33]).

Parkinson's disease

The observation that 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a product of meperidine analogue synthesis, can cause the development of chronic parkinsonism [34, 35] drew attention to the involvement of a mitochondrial dysfunction in PD, for 1-methyl-4-phenylpyridinium ion (MPP^+), the toxic metabolite of MPTP [36, 37], has been shown to be capable of the selective inhibition of complex I of the mitochondrial ETC [38, 39]. Later, a significant decrease in complex I activity was observed in the substantia nigra and platelets of patients with idiopathic PD [40, 41], though the currently available experimental data suggest some inconsistency (reviewed in [42]). Nevertheless, the possible role of exposure to pesticides (with consequent complex I inhibition and/or reactive oxygen intermediate (ROI) generation) in the development of idiopathic PD (reviewed in [43]) provides further evidence of the crucial role of a mitochondrial dysfunction in the disease pathogenesis. Indeed, the proved Fe^{2+} accumulation in PD SNpc appears to be a factor aggravating the oxidative damage (reviewed in [44–46]). In consequence of genetic mutations, the deteriorated function of several gene products (*e.g.* α-synuclein, parkin, phosphatase and tensin homologue induced putative kinase 1 [PINK1], high-temperature requirement protein A2

© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd



Fig. 1 Oxidative stress and mitochondrial impairment in PD and HD (for details see the text). 3-NP: 3-nitropropionic acid; ADP: adenosine diphosphate; ATP: adenosine triphosphate; CI-IV: mitochondrial ETC complexes I-IV; CAT: catalase; cyt: cytochrome; $FADH_2$: reduced flavin adenine dinucleotide; Fe_xS_y: iron-sulfur cluster; $FMNH_2$: reduced flavin mononucleotide; GPX: glutathione peroxidase; GSH: reduced glutathione; GSSG: oxidized glutathione; H_2O_2: hydrogen peroxide; HtrA2: high-temperature requirement protein A2; mNOS: mitochondrial nitric oxide synthase; MPT: mitochondrial permeability transition; mtDNA: mitochondrial deoxyribonucleic acid; MPP^+: 1-methyl-4-phenylpyridinium ion; · NO: nitric oxide; $O_2^{\cdot -}$: superoxide anion; ·OH: hydroxyl radical; $ONOO^-$: peroxynitrite anion; Q: oxidized coenzyme Q_{10}; ·QH: semiquinone coenzyme Q_{10}; QH_2: reduced coenzyme Q_{10}; PINK: phosphatase and tensin homologue-induced putative kinase 1; POLG1: mtDNA polymerase γ1; SOD: superoxide dismutase.

(HtrA2)/Omi, DJ-1, leucine-rich repeat kinase 2 [LRRK2] and mitochondrial DNA [mtDNA] polymerase γ1 [POLG1]) can additionally contribute to the development of PD by affecting the mitochondria too (Fig. 1), amongst other subcellular compartments (reviewed in [42, 47, 48]). The mitochondrial accumulation of α-synuclein under pathological conditions results in decreased complex I activity and the increased production of ROI in human dopaminergic neurons [49]. The decrease in parkin function may result in a reduced mitochondrial antioxidant capacity [50]. PINK1 is able reduce the cytochrome c release from the mitochondria by phosphorylating tumour necrosis factor receptor-associated protein 1, thereby inhibiting oxidative stress-induced apoptosis. Furthermore, PINK1 has been shown to be able to phosphorylate both parkin [51] and HtrA2/Omi [52]; the regulation of the proteolytic activity of the latter may result in resistance to mitochondrial stress. DJ-1 acts as an atypical peroxiredoxin-like peroxidase and its dysfunction results in impaired mitochondrial ROI scavenging [53]. The available data [54] support the possibility of LRRK2 action at the mitochondria, but the mechanism has not yet been clarified. Mutations in POLG1 render mtDNA more vulnerable to oxidative damage, resulting in a mitochondrial dysfunction, and thus these mutations may also be associated with the development of PD [55].

Huntington's disease

An early finding suggestive of the involvement of a mitochondrial dysfunction in the development of HD was a decreased activity of succinate dehydrogenase (complex II of the ETC) in post-mortem

© 2011 The Authors

Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd

HD brains [56]. It was later observed that a plant/fungal toxin, 3-nitropropionic acid (3-NP), which is capable of the irreversible inhibition of succinate dehydrogenase [57], causes extrapyramidal symptoms due to food poisoning [58]. This toxin and the reversible enzyme inhibitor malonate [59] were therefore widely applied in the animal modelling of HD [60–62]. Mutant huntingtin has been shown to be able to bind directly to mitochondria, thereby altering their normal function [63] (Fig. 1). The impaired mitochondrial Ca^{2+} handling [64] and the repression of transcription factors, *e.g.* that responsible for peroxisome proliferator-activated receptor γ coactivator 1-α (involved in the regulation of gene expression related to mitochondrial biogenesis and respiration) [65], are certainly associated with the mitochondrial dysfunction in HD.

Glutamate excitotoxicity in neurodegeneration

Background

The toxic effects of glutamate, the main excitatory amino acid in the brain, were first observed in 1957 [66], and the term glutamate-induced excitotoxicity was introduced by Olney in 1969 [67]. Besides their role in physiological signal transduction, the ionotropic and metabotropic glutamate receptors take part in pathological excitotoxic processes too (reviewed in [68]; Fig. 2). The N-methyl-D-aspartate (NMDA) receptors (NMDARs) seem to play the central role in excitotoxicity. The available data suggest that the activation of NMDARs (which facilitates the entry of cations, and in particular Ca^{2+}, into the neurons) at the extrasynaptic site is neurotoxic, whereas synaptic NMDAR activation promotes neuronal survival [69]. A conventional NMDAR is composed of 2 NMDAR subunit 1s (NR1s) and 2 NMDAR subunit 2s (NR2s), forming a heterotetramer. The NR1s form the ion channel, whereas the NR2s (NR2A-D) have more of a regulatory and refining role. It has been shown that the NR2B-containing NMDARs predominate at the extrasynaptic site [70], and there is accumulating evidence that glutamate-induced excitotoxicity is mainly mediated by these NR2B-containing NMDAR channels [71]. The α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors (AMPARs) are composed of a combination of GluR1–4 subunits, whereas the kainate receptors consist of subunits GluR5–7. The cation permeability profile shows Ca^{2+} permeability for the AMPARs too, with the exception of those containing the GluR2 subunit. Conversely, the kainate receptors are mostly impermeable to Ca^{2+}. The activation of AMPARs and kainate receptors can be associated with both NMDAR function and dysfunction by inducing relief of the Mg^{2+} blockade of the NMDAR channel. The metabotropic glutamate receptors (mGluR1–8) can be classified into three groups; their functions are mainly linked to G-proteins. The activation of group I mGluRs (mGluR1 and mGluR5) results in intracellular Ca^{2+} mobilization through inositol triphosphate (IP_3) production, leading to IP_3 receptor 1 (IP_3R1) activation on the endoplasmatic reticulum (ER) [72, 73]. This can accompany the pathological Ca^{2+} signalling characteristic of glutamate excitotoxicity. The activation of group II mGluRs (mGluR2–3) and group III mGluRs (mGluR4, mGluR6–8) leads to the downstream inhibition of voltage-dependent Ca^{2+} channels [74], thereby decreasing glutamate release. The dysfunction or down-regulation of these receptors may result in an enhanced release of glutamate. The alterations in glutamate uptake mediated by glutamate transporters (EAAT1–5: excitatory amino acid transporter 1–5), and especially EAAT1 [glutamate aspartate transporter (GLAST)] and EAAT2 [glutamate transporter-1 (GLT-1)], may also result in an elevation of extracellular glutamate concentration accompanying the excitotoxic process (reviewed in [75]; Fig. 2). However, this elevation is not absolutely necessary for excitotoxicity. An energy impairment due to a mitochondrial dysfunction and/or oxidative stress can also lead to partial membrane depolarization, resulting in relief of the Mg^{2+} blockade of the NMDAR channel (Fig. 2). Thus, even in physiological concentrations, glutamate can evoke downstream events such as a Ca^{2+} overload and free radical generation, inducing a self-propagating process [76]. The downstream events evoked by a Ca^{2+} overload certainly involve mitochondrial Ca^{2+} sequestration with a consequential impairment of the mitochondrial function, ER stress, pathological overactivation of several types of kinases and/or phosphatases, proteases (*e.g.* caspases and calpains), neuronal nitric oxide synthase (nNOS), endonucleases, phospholipases and transglutaminases, leading to detrimental effects (reviewed in [77]).

Parkinson's disease

A recently published paper [78] dealing with the dysregulation of glutamate homeostasis in the mouse SNpc due to chronic MPTP treatment provided evidence of glutamate excitotoxicity involvement in PD pathogenesis secondary to a mitochondrial dysfunction (commented in [79]). Neurons in the SNpc possess glutamate receptors and receive glutamatergic input from the subthalamic nucleus (the main input), cerebral cortex, amygdala and pedunculopontine and laterodorsal tegmental nuclei (reviewed in [80]). The metabolic compromise leads to a decrease in striatal dopaminergic innervation, resulting in overactivation of the subthalamic nucleus. This causes an increase in glutamate release onto the compromised dopaminergic neurons in the SNpc (reviewed in [81]). Hence, the excitotoxic cascade further worsens the neurodegenerative process, inducing a vicious cycle.

Huntington's disease

The results of kainic acid experiments suggested that glutamate excitotoxicity may play an important role in the development of HD [82, 83]. Subsequent experiments with ibotenic acid [84] and quionolinic acid (QUIN) [85, 86] furnished evidence in support of this. To explain the selective impairment of the MSNs, it should be borne in mind that they receive a massive glutamatergic input from

© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd



Fig. 2 The pathomechanism of glutamate excitotoxicity influenced by the neuroactive kynurenines (for details see the text). 3-OH-L-KYN: 3-hydroxy-L-kynurenine; α7-nAChR: α7-nicotinic acetylcholine receptor; AMPAR: α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor; EAAT1–2: excitatory amino acid transporter 1–2; ER: endoplasmic reticulum; Glu: L-glutamate; IP_3R1: inositol triphosphate receptor 1; kainate R: kainate receptor; KYNA: kynurenic acid; mGluRI-III: group I-III metabotropic glutamate receptors; NMDAR: N-methyl-D-aspartate receptor; nNOS: neuronal nitric oxide synthase; QUIN: quinolinic acid.

the cortex [87] and the thalamus (reviewed in [88]). As the NMDA receptors are to be found in especially high amount on the spines of the MSNs [89], these neurons are rather sensitive to glutamate [90, 91], which explains the extremely extensive loss of striatal neurons expressing NMDARs [92]. Furthermore, the expression pattern of the receptor subunits differs from those of the other striatal neurons [89, 93], as the extrasynaptic NMDARs of MSNs preferentially contain the NR2Bs [94, 95]. The expression of mutant huntingtin can sensitize the NR2B-containing NMDARs [96, 97], thereby aggravating the excitotoxic process [98] (Fig. 2). Additionally, the polyglutamine expansion has been found to interfere with the ability of huntingtin to interact with the post-synaptic density protein of 95 kD (PSD95) [99], a structural link between nNOS and NMDARs [100], which also results in the sensitization of NMDARs. Indeed, the glutamate uptake is reduced in HD [101], and the experimental data suggest that the reduced expression of mGluR2s may lead to an increase in glutamate release [102], ensuring the possibility of enhanced activation through the sensitized NMDARs. Further, mutant huntingtin can increase Ca^{2+} release from the ER, by binding to the IP_3R1s [103].

The kynurenine pathway

Historical overview

L-Kynurenine (L-KYN) is a central intermediate in the main pathway of the tryptophan (TRP) metabolism [104]; it was first identified in rabbit urine [105]. More than 95% of TRP is metabolized through kynurenines [106]. This pathway is responsible for the production of nicotinic acid [107], a major component of NAD^+ and nicotinamide adenine dinucleotide phosphate ($NADP^+$) coenzymes. L-KYN can be metabolized in three distinct ways to kynurenic acid (KYNA), anthranilic acid (ANA) and 3-hydroxy-L-kynurenine (3-OH-L-KYN). KYNA, which has been identified in dog urine [108], is a side-product of the main metabolic route [109], while ANA and 3-OH-L-KYN, first identified in 1941 and in 1949, respectively [110, 111], can be further metabolized in some steps through an important intermediate, QUIN [112, 113], to NAD^+ in a common pathway (Fig. 3). As regards the role of kynurenines in the CNS, it is important to highlight that L-KYN is present in the

© 2011 The Authors

Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd



Fig. 3 The kynurenine pathway of the tryptophan metabolism. NAD^+: nicotinamide adenine dinucleotide.

mammalian brain tissue in a concentration of around 200 ng/g. A total of 40% of it is formed locally, and 60% is taken up from the periphery [114, 115] as a consequence of its being able to cross the blood–brain barrier [116, 117] by the large neutral amino acid carrier, a process studied in detail by Fukui *et al.* [118]. The metabolites have also been detected in the mammalian brain [115, 119], in which KYNA, 3-OH-L-KYN and QUIN are commonly referred to as neuroactive kynurenines (reviewed in [120–122]). The potential role of kynurenines in depression was suggested in 1973 [123], but the first direct evidence of neuroactive properties, such as convulsive and stimulatory effects, was demonstrated only in 1978 [124].

The biosynthesis of neuroactive kynurenines

KYNA is produced from its precursor, L-KYN, in an irreversible transamination by the action of four subtypes of kynurenine

© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd

aminotransferases (KATs; reviewed in [125]): KAT-I-II [126], KAT-III [127] and mitochondrial aspartate aminotransferase (mitAAT, also called KAT-IV) [128]. KAT-II has been demonstrated to be the main KYNA-producing enzyme in the rat and human brains, whereas in the mouse brain KAT-II surprisingly possesses the lowest activity and mitAAT the highest [128]. The KATs are abundantly expressed in the astrocytes [129], but only weak granular staining can be seen in the neurons [130]. The development of KAT-II-specific antibodies revealed that the expression of this enzyme subtype is confined entirely to the astrocytes [131]. 3-OH-L-KYN is formed by the action of kynurenine 3-hydroxylase [132], whereas QUIN is produced by 3-hydroxyanthranilate 3,4-dioxygenase [133]. This branch of the kynurenine pathway is mainly localized in the microglia and macrophages [134], whereas astrocytes do not express kynurenine 3-hydroxylase, but only 3-hydroxyanthranilate 3,4-dioxygenase [129].

Neuroactive kynurenines: sites of action

KYNA exerts broad-spectrum endogenous antagonism on ionotropic excitatory amino acid receptors [135] (Fig. 2). In micromolar concentrations, it acts as a competitive antagonist at the strychnine-insensitive glycine-binding site of the NMDAR [136] and displays weak antagonistic effects on the AMPARs and kainate receptors [137]. KYNA has been found to be capable of facilitating AMPAR responses in low (nanomolar to micromolar) concentrations [138], but the concentration range is controversial: KYNA in micromolar concentrations has recently been shown to have neuroinhibitory effects, whereas in nanomolar concentrations it was claimed to be a facilitator [139]. In addition to its direct effects on glutamate receptors, KYNA non-competitively blocks the α7-nicotinic acetylcholine receptors [140], presynaptic activation of which is involved in the regulation of glutamate release [141]. It has been reported that, through activation at the G protein-coupled receptor GPR35, KYNA can elicit IP_3 production and Ca^{2+} mobilization [142], but the role of this phenomenon is questionable as regards the CNS, because GPR35 exhibits a limited expression in the brain and a relatively high KYNA concentration is necessary for activation. With respect to the KATs, it is interesting that the neuronal expression of KAT-I appears to have effects on developmental processes, such as programmed cell death [143]. QUIN is a weak, but specific competitive agonist of the NMDAR subgroup containing the NR2A and NR2B subunits, with low receptor affinity [144]. There are 2 mechanisms *via* which it can cause excitotoxicity modulating the glutamatergic system: the direct activation of NMDARs [145] or the release and uptake inhibition of glutamate [146, 147] (Fig. 2). The production of ROI [148] and lipid peroxydation due to QUIN also contribute to its neurotoxic effects [149]. The deleterious effects of 3-OH-L-KYN are mediated by free radicals and not glutamate receptors [150, 151] (Fig. 2). Some of its detrimental actions may be due to its metabolite, 3-hydroxyanthranilic acid, which readily undergoes auto-oxidation with the production of O_2^- [152], and it has also been shown to be neurotoxic [153].

Neuroactive kynurenines in neurodegenerative disorders

Parkinson's disease

The involvement of kynurenine pathway abnormalities in the pathogenesis of PD is suggested by the findings that 3-OH-L-KYN concentrations have been found to be elevated in the frontal cortex, putamen and SNpc of patients with PD, probably contributing to the oxidative damage [154]. Conversely, KYNA concentrations are decreased. Accordingly, a reduction in KAT-I in the SNpc of mice has been observed after MPTP treatment [155]. Furthermore, administration of 6-hydroxydopamine (a free radical generator in catecholaminergic neurons) considerably diminishes not only tyrosine hydroxylase, but also KAT-I immunoreactivity in the remaining SNpc neurons [156]. In rat cerebral cortical slices, MPP^+ appreciably decreased KAT-II activity, with the resulting depletion of KYNA [157].

Huntington's disease

There is a seeming imbalance of the tryptophan metabolism in the striatum in different stages of the disease. A relative decrease in KYNA level and reduced activity of KATs have been demonstrated in the striatum of HD patients [158–160]. The cerebrospinal fluid level of KYNA has also been observed to be decreased in HD [161]. The elevation in QUIN concentration in the early stages correlates well with the increased activity of its producing enzyme, 3-hydroxyanthranilate 3,4-dioxygenase, in HD brains [162]. The fact that the intrastriatal injection of QUIN is highly applicable for the animal modelling of HD [85, 86, 163] well supports its pathogenetic role in HD development (reviewed in [164]). In correlation with the findings detailed above, young mice with the targeted deletion of KAT-II, showing decreased KYNA and normal 3-OH-L-KYN and QUIN concentrations, displayed an increased vulnerability to the intrastriatal injection of QUIN as compared with the wild-type controls, suggesting the importance of KYNA in controlling the neurotoxicity of QUIN [165]. The striatal concentration of 3-OH-L-KYN changes in parallel with the QUIN level in HD [160, 166], and it has been shown to potentiate the neurotoxic effects of QUIN in the rat striatum [167]. After 3-NP treatment, the activity of KAT-I is reduced most markedly in the striatum of the rat brain, suggesting a link between the metabolic disturbances and an altered tryptophan metabolism in HD [168]. Furthermore, the use of rat cerebral cortical slices proved that the activities of KAT-I and KAT-II were decreased [157]. The results of a yeast genomic screen indicated that deletion of the KYNA-producing enzyme enhances mutant huntingtin-mediated toxicity, whereas it is ameliorated mainly by the deletion of 3-OH-L-KYN, but also by that of the QUIN-producing enzyme [169].

© 2011 The Authors

Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd

Endogenous neuroprotection in Parkinson's and Huntington's diseases

Background

PD is one of the few neurodegenerative disorders for which effective symptomatic therapies are available, whereas in HD, the proposed symptomatic therapies are few and have limited effects. The main aim of preclinical and clinical studies in this field is to achieve neuroprotection (preservation of the neuronal structure and function) or at least to provide highly effective symptomatic treatment. Amongst the therapeutic strategies, a popular approach is to attain neuroprotection by the exogenous administration of endogenously occurring natural substances or their derivatives with slight modifications. L-3,4-dihydroxyphenylalanine (L-DOPA), the compound most widely used as symptomatic therapy in PD, is a good example of this approach. Although there have been numbers of preclinical and clinical studies on both PD and HD (reviewed in [170–173]), we mention here only the forms of endogenous neuroprotection confined to the prevention of oxidative stress, energy impairment and glutamate excitotoxicity.

L-carnitine

L-carnitine plays a role in the mitochondrial exchange of fatty acids; it has direct or indirect antioxidant properties (reviewed in [174]). It has proved to be protective in cell culture against MPP^+ [175], and its derivative, acetyl-L-carnitine, also exerts beneficial effects in the MPTP model of PD in primates [176], and in a cellular toxin model of PD [177]. Although L-carnitine suppresses 3-NP-induced MPT [178], and is neuroprotective in a transgenic mouse model of HD [179], low-dose acetyl-L-carnitine administration in a double-blind, placebo-controlled study showed no benefit [180].

L-carnosine

L-carnosine (β-alanyl-L-histidine) is a dipeptide with demonstrated antioxidant, antiglycator and metal chelator properties (reviewed in [181]). In a pilot study, L-carnosine increased the efficacy of L-DOPA treatment in PD patients [182]. In a transgenic mouse model of HD, L-carnosine was unable to improve the survival or the motor performance of mice significantly (our unpublished data).

Coenzyme Q_{10}

Coenzyme Q_{10} is a lipid-soluble benzoquinone that functions as an electron transporter in the ETC and as an antioxidant. Coenzyme Q_{10} has also been demonstrated to be effective in the MPTP model of PD [183] and in the transgenic mouse models of HD [184, 185]. Whereas low-dose administration was ineffective [186], higher doses of coenzyme Q_{10} exerted beneficial effects in early PD patients in a phase II, multicentre, randomized, parallel-group, placebo-controlled, double-blind, dosage-ranging clinical trial [187] and in a monocentre, parallel-group, placebo-controlled, double-blind trial [188]. Surprisingly, a later multicentre, randomized, parallel-group, placebo-controlled, double-blind, stratified, single-dose trial in mid-stage PD did not indicate any significant amelioration [189]. A randomized, placebo-controlled, phase III trial was recently initiated. A multicentre, randomized, parallel-group, double-blind trial [Coenzyme Q10 And Remacemide Evaluation in Huntington's Disease (CARE-HD)] was unable to prove any significant effect on the functional decline in early HD, in contrast with an apparent amelioration tendency [190]. This might be due to underdosing; the Pre2CARE study has revealed that higher doses of coenzyme Q_{10} are reasonably well tolerated [191]. A larger study (2CARE) is currently ongoing for the re-evaluation of coenzyme Q_{10} in HD.

Creatine

Creatine kinase and its substrates creatine and phosphocreatine take part in the buffering of intracellular energy reserves (reviewed in [192]) and in the inhibition of MPT activation [193]. The exogenous administration of creatine proved effective in the MPTP model of PD [194] and the 3-NP, malonate [195] and transgenic mouse models [196, 197] of HD. Nevertheless, a randomized, double-blind phase II trial in early PD [198, 199] and a placebo-controlled randomized pilot trial [200] did not indicate any robust clinical benefit. A phase III, long-term (5 year follow-up), multicentre, double-blind, placebo-controlled study [The National Institutes of Health Exploratory Trials in Parkinson Disease Long-term Study 1 (NET-PD LS1)] is currently ongoing. As regards HD, creatine was not found to be significantly effective either in a 2 year open label pilot study [201, 202] or in a placebo-controlled pilot trial [203], likewise in PD. A high-dose phase III creatine trial started in 2008.

Cysteamine/cystamine

Cysteamine, an antioxidant, is capable of the prevention of lipid peroxidation and can exert beneficial effects through its action on enzymes responsible for the maintenance of an antioxidant milieu or energy preservation [204, 205]. Its oxidized form, cystamine, exerts a transglutaminase inhibitory effect (reviewed in [206]). An early study was unable to detect any protective effect of cysteamine in the MPTP model [207], but it has recently been proved that lower doses of both cysteamine and cystamine show efficacy [208, 209]. Treatment with cystamine afforded neuroprotection in transgenic mouse models of HD [210–212]. A phase I dose finding and tolerability study [Phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease (CYTE-I-HD)] has already been carried out with cysteamine in HD patients [213].

Eicosapentaenoic acid

Eicosapentaenoic acid (EPA) is an essential n-3 polyunsaturated fatty acid that targets the mitochondrial function, especially by

© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd

acting on peroxisome proliferator activated receptors (reviewed in [214]). It has been shown that the administration of polyunsaturated fatty acid mixtures containing EPA improves dyskinesias and reverses weight loss in HD patients [215] and is beneficial in a transgenic mouse model of HD [216]. A randomized, double-blind, placebo-controlled study also demonstrated beneficial effects [217]. Although treatment with the ethyl ester of EPA (ethyl-EPA) improved the motor dysfunction in a transgenic mouse model of HD [218], and also led to an MRI and neuropsychological improvement [219] and a significant reduction in brain atrophy, particularly in the caudate and thalamus [220], a randomized, double-blind, placebo-controlled study indicated no benefit [221]. At present, The Huntington Study Group is conducting a multicentre, randomized, double-blind, placebo-controlled trial with ethyl-EPA [randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease (TREND-HD)]. The preliminary data revealed no efficacy after 6 months [222].

α-lipoic acid

α-lipoic acid is a disulfide compound that serves as a coenzyme for mitochondrial pyruvate dehydrogenase and α-ketoglutarate dehydrogenase complexes. It exerted beneficial effects in the transgenic mouse model of HD [223] and in a cellular toxin model of PD [177].

Pyruvate

Pyruvate is the end-metabolite of glycolysis and serves as an energy substrate. Pyruvate and its simple derivative ethyl-pyruvate provided protection against MPP^+ toxicity *in vitro* [224, 225], but we did not observe any protection against MPTP in mice. Pyruvate also exerted neuroprotective effects in the QUIN rat model of HD [226].

Taurine

Taurine is a β-amino acid with antioxidant properties (reviewed in [227]). Although it has been found to be protective in the 3-NP model of HD [228], we did not observe any beneficial effects either in the MPTP model of PD, or in a transgenic mouse model of HD (our unpublished data).

Tocopherol

α-tocopherol (the predominant form of vitamin E in the tissues and in supplements) is a lipid-soluble antioxidant which, despite the great expectations, was reported to be ineffective both in animal MPTP models of PD [207, 229], and in PD patients in the large, randomized, placebo-controlled Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism (DATATOP) study [230]. However, it has also been shown that α-tocopherol is capable of attenuating 6-hydroxydopamine lesions [231] and iron-induced nigral neuron loss [232]. Furthermore, a pilot trial of high-dose α-tocopherol and ascorbate demonstrated beneficial effects in PD patients [233]. Nevertheless, a double-blind, placebo-controlled study did not confirm the efficacy of high-dose α-tocopherol in HD patients, though it would be beneficial for patients early in the course [234]. Interestingly, γ-tocopherol (the predominant form of vitamin E in the diet) effected a considerably larger attenuation than the statistically ineffective α-tocopherol as concerns MPTP-induced dopamine loss [235].

L-KYN/KYNA

From a therapeutic aspect, enhancement of the effects of KYNA would be a successful therapeutic strategy providing protection against the effects of neurotoxic 3-OH-L-KYN and QUIN. This may be achieved by administration of the KYNA precursor L-KYN. Thus, a combination of the blood–brain barrier-penetrable L-KYN with nicotinylalanine, an agent that inhibits both kynurenine 3-hydroxylase and kynureninase activity, and with probenecid, an inhibitor of organic acid transport for enhancement of the brain KYNA concentration, exerted protective effects in the SNpc against both NMDA and QUIN-induced excitotoxicity [236], and in the striatum against QUIN-mediated neurotoxicity [237], possibly *via* the elevated level of KYNA. However, the co-administration of probenecid seems necessary to achieve a considerably elevated KYNA level in the field of interest. Although L-KYN alone was able to induce amelioration in animal models of cerebral ischemia [238, 239], it is mainly used in combination with probenecid to achieve neuroprotection (*e.g.* in a migraine model: [240]). However, it has recently been shown that probenecid alone can mitigate the alterations in that migraine model [241]. Further, probenecid is protective in a transgenic mouse model of HD [242], whereas L-KYN alone is ineffective (our unpublished data). In an MPTP model of PD, we did not find any protection with pure L-KYN either. Nevertheless, the available data suggest that L-KYN in combination with probenecid is perhaps capable of enhancing neuroprotection in chronic neurodegenerative disorders.

Although the direct injection of KYNA into the globus pallidus internus [243, 244], or its co-infusion with either QUIN or NMDA into the SNpc [236], resulted in beneficial effects in PD models, the systemic administration of KYNA does not seem to be a good therapeutic approach in CNS disorders for several reasons. It penetrates the blood–brain barrier poorly [118], and it undergoes rapid clearance from the brain and the body, mediated by organic anion transporters [245]. To overcome these disadvantages, numbers of KYNA derivatives have been synthetized with preserved or enhanced pharmacodynamic properties (reviewed in [246–248]). Although 7-chlorokynurenic acid (7-Cl-KYNA), which has enhanced antagonism at glycine/NMDA receptors, did not exert any protection against the intrastriatal neurotoxic effect of MPP^+ in rats, whereas KYNA did [249], the systemic administration of 4-chlorokynurenine (4-Cl-KYN), the blood–brain barrier-penetrable pro-drug of 7-Cl-KYNA, did prevent QUIN- and malonate-induced neurotoxicity

© 2011 The Authors

Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd

in the rat striatum [250]. The apparent contradiction between these experimental findings may be resolved in that 4-Cl-KYN can be metabolized to 4-chloro-3-hydroxyanthranilate, a powerful inhibitor of QUIN synthesis [251], which broadens the modes of neuroprotective action. Furthermore, the divergence between the KYNA and 7-Cl-KYNA effects can be explained in that the halogenation of KYNA results in compounds that are highly selective for the glycine site of NMDARs [252] and can mainly prevent NMDAR-mediated excitotoxicity, whereas a wider spectra of neurotransmitter receptors are involved in neurodegenerative processes. The KYNA amides seem to be excellent candidates, as they may be capable of the selective inhibition of the NR2B subunit-containing NMDARs too [253]. A newly synthesized KYNA amide, previously proved to be beneficial in migraine [254] and epilepsy [255] models, exerts neuroprotection in a transgenic mouse model of HD [256].

Concluding remarks

Although PD and HD are different clinical entities, their pathomechanisms reveal several common features. The main characteristic symptoms involve disturbances in motion in both cases, with an underlying dysfunction of the very complex motor system, mainly the basal ganglia. Oxidative stress with mitochondrial impairment and glutamate excitotoxicity are definitely involved in the disease development. Although these pathogenetic factors are closely connected to each other, and each can be evoked by the other, oxidative stress and mitochondrial impairment appear to play the predominant role in PD pathogenesis, whereas glutamate excitotoxicity does so in HD pathogenesis. Accordingly, the therapeutic strategies mainly target these two possibilities. As concerns endogenous neuroprotection, the main modes involve naturally occurring agents and their slightly modified derivatives, and in particular substances for the achievement of antioxidant protection and the preservation of the mitochondrial function and energy stores. These agents, such as L-carnitine, L-carnosine, coenzyme Q_{10}, creatine, cysteamine/cystamine, EPA, α-lipoic acid, pyruvate, taurine and tocopherol, all serve as potential therapeutics. However, in contrast with the promising preclinical findings, most of them did not exhibit unequivocal significant efficacy in clinical trials. This could be due to the lack of optimum dosing or an improper study design, but it is very important to pay special attention to the validity of the experimental models and to the heterogeneity of the human population and of the disease development. There is still a major need for further studies with natural or newly designed agents in order to achieve a significant level of neuroprotection, or at least a certain symptomatic benefit. As concerns the kynurenines, KYNA would serve as a good anti-excitotoxic agent by virtue of its wide-spectrum pharmacodynamic profile and low potency of inducing side-effects. However, there is a major need to improve the pharmacokinetic profile in order to attain an acceptable half-life and a better blood–brain penetrance. Thanks to a systematic molecule design, KYNA derivatives will hopefully exhibit therapeutic potency in both preclinical and clinical studies.

Acknowledgements

Funding of the studies reported in the paper: Teller Ede (NAP-BIO-06-BAY-BIOSZ), ETT 026-04, TáMOP-4.2.2.-08/1/2008-2002, OTKA K75628 and cNEUPRO (LSHM-CT-2007-037950).

Conflict of interest

The authors confirm that there are no conflicts of interest.

References

1. **Parkinson J.** An essay on the shaking palsy. London: Sherwood, Neely and Jones; 1817.
2. **Porter B, Macfarlane R, Unwin N, *et al.*** The prevalence of Parkinson's disease in an area of North Tyneside in the North-East of England. *Neuroepidemiology*. 2006; 26: 156–61.
3. **Walker RW, Hand A, Jones C, *et al.*** The prevalence of Parkinson's disease in a rural area of North-East England. *Parkinsonism Relat Disord*. 2010; DOI: 10.1016/j.parkreldis.2010.07.002.
4. **Peters CM, Gartner CE, Silburn PA, *et al.*** Prevalence of Parkinson's disease in metropolitan and rural Queensland: a general practice survey. *J Clin Neurosci*. 2006; 13: 343–8.
5. **de Lau LM, Breteler MM.** Epidemiology of Parkinson's disease. *Lancet Neurol*. 2006; 5: 525–35.
6. **Rodriguez-Oroz MC, Jahanshahi M, Krack P, *et al.*** Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. *Lancet Neurol*. 2009; 8: 1128–39.
7. **Braak H, Del Tredici K, Rub U, *et al.*** Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol Aging*. 2003; 24: 197–211.
8. **Huntington G.** On Chorea. *Med Surg Reporter*. 1872; 26: 320–1.
9. **The Huntington's Disease Collaborative Research Group.** A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. *Cell*. 1993; 72: 971–83.
10. **Folstein SE, Chase GA, Wahl WE, *et al.*** Huntington disease in Maryland: clinical aspects of racial variation. *Am J Hum Genet*. 1987; 41: 168–79.
11. **Sepcic J, Antonelli L, Sepic-Grahovac D, *et al.*** Epidemiology of Huntington's disease in Rijeka district, Yugoslavia. *Neuroepidemiology*. 1989; 8: 105–8.
12. **Evers-Kiebooms G, Nys K, Harper P, *et al.*** Predictive DNA-testing for Huntington's disease and reproductive decision making:

© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd

a European collaborative study. *Eur J Hum Genet*. 2002; 10: 167–76.
13. **Peterlin B, Kobal J, Teran N, *et al.*** Epidemiology of Huntington's disease in Slovenia. *Acta Neurol Scand*. 2009; 119: 371–5.
14. **Gardian G, Vecsei L.** Huntington's disease: pathomechanism and therapeutic perspectives. *J Neural Transm*. 2004; 111: 1485–94.
15. **Walker FO.** Huntington's disease. *Lancet*. 2007; 369: 218–28.
16. **Thompson PD, Berardelli A, Rothwell JC, *et al.*** The coexistence of bradykinesia and chorea in Huntington's disease and its implications for theories of basal ganglia control of movement. *Brain*. 1988; 111: 223–44.
17. **van Vugt JP, van Hilten BJ, Roos RA.** Hypokinesia in Huntington's disease. *Mov Disord*. 1996; 11: 384–8.
18. **Vonsattel JP, Myers RH, Stevens TJ, *et al.*** Neuropathological classification of Huntington's disease. *J Neuropathol Exp Neurol*. 1985; 44: 559–77.
19. **Ferrante RJ, Kowall NW, Beal MF, *et al.*** Selective sparing of a class of striatal neurons in Huntington's disease. *Science*. 1985; 230: 561–3.
20. **Ferrante RJ, Kowall NW, Richardson EP Jr, *et al.*** Topography of enkephalin, substance P and acetylcholinesterase staining in Huntington's disease striatum. *Neurosci Lett*. 1986; 71: 283–8.
21. **Reiner A, Albin RL, Anderson KD, *et al.*** Differential loss of striatal projection neurons in Huntington disease. *Proc Natl Acad Sci USA*. 1988; 85: 5733–7.
22. **Centonze D, Bernardi G, Koch G.** Mechanisms of disease: basic-research-driven investigations in humans – the case of hyperkinetic disorders. *Nat Clin Pract Neurol*. 2007; 3: 572–80.
23. **Sas K, Robotka H, Toldi J, *et al.*** Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. *J Neurol Sci*. 2007; 257: 221–39.
24. **Sas K, Pardutz A, Toldi J, et al.** Dementia, stroke and migraine – some common pathological mechanisms. *J Neurol Sci*. 2010: DOI: 10.1016/j.parkreldis.2010.07.002.
25. **Beckman JS, Beckman TW, Chen J, *et al.*** Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. *Proc Natl Acad Sci USA*. 1990; 87: 1620–4.
26. **Coyle JT, Puttfarcken P.** Oxidative stress, glutamate, and neurodegenerative disorders. *Science*. 1993; 262: 689–95.
27. **Green DR, Reed JC.** Mitochondria and apoptosis. *Science*. 1998; 281: 1309–12.
28. **Beal MF.** Energetics in the pathogenesis of neurodegenerative diseases. *Trends Neurosci*. 2000; 23: 298–304.
29. **Ankarcrona M, Dypbukt JM, Bonfoco E, *et al.*** Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. *Neuron*. 1995; 15: 961–73.
30. **Leist M, Single B, Castoldi AF, *et al.*** Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. *J Exp Med*. 1997; 185: 1481–6.
31. **Soane L, Kahraman S, Kristian T, *et al.*** Mechanisms of impaired mitochondrial energy metabolism in acute and chronic neurodegenerative disorders. *J Neurosci Res*. 2007; 85: 3407–15.
32. **Li P, Nijhawan D, Budihardjo I, *et al.*** Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. *Cell*. 1997; 91: 479–89.
33. **Schrader K, Huai J, Jockel L, *et al.*** Non-caspase proteases: triggers or amplifiers of apoptosis? *Cell Mol Life Sci*. 2010; 67: 1607–18.
34. **Langston JW, Ballard P, Tetrud JW, *et al.*** Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. *Science*. 1983; 219: 979–80.
35. **Langston JW, Ballard PA Jr.** Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. *N Engl J Med*. 1983; 309: 310.
36. **Chiba K, Trevor A, Castagnoli N Jr.** Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. *Biochem Biophys Res Commun*. 1984; 120: 574–8.
37. **Langston JW, Irwin I, Langston EB, *et al.*** 1-Methyl-4-phenylpyridinium ion (MPP+): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. *Neurosci Lett*. 1984; 48: 87–92.
38. **Nicklas WJ, Vyas I, Heikkila RE.** Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. *Life Sci*. 1985; 36: 2503–8.
39. **Mizuno Y, Sone N, Saitoh T.** Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion on activities of the enzymes in the electron transport system in mouse brain. *J Neurochem*. 1987; 48: 1787–93.
40. **Reichmann H, Riederer P.** Biochemical analyses of respiratory chain enzymes in different brain regions of patients with Parkinson's disease. BMFT Symposium "Morbus Parkinson und andere Basalganglienerkrankungen". Bad Kissingen; 1989. p. 44 (abstract).
41. **Schapira AH, Cooper JM, Dexter D, *et al.*** Mitochondrial complex I deficiency in Parkinson's disease. *Lancet*. 1989; 1: 1269.
42. **Banerjee R, Starkov AA, Beal MF, *et al.*** Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. *Biochim Biophys Acta*. 2009; 1792: 651–63.
43. **Hatcher JM, Pennell KD, Miller GW.** Parkinson's disease and pesticides: a toxicological perspective. *Trends Pharmacol Sci*. 2008; 29: 322–9.
44. **Gotz ME, Double K, Gerlach M, *et al.*** The relevance of iron in the pathogenesis of Parkinson's disease. *Ann NY Acad Sci*. 2004; 1012: 193–208.
45. **Lee DW, Andersen JK.** Iron elevations in the aging Parkinsonian brain: a consequence of impaired iron homeostasis? *J Neurochem*. 2010; 112: 332–9.
46. **Rivera-Mancia S, Perez-Neri I, Rios C, *et al.*** The transition metals copper and iron in neurodegenerative diseases. *Chem Biol Interact*. 2010; 186: 184–99.
47. **Schapira AH.** Mitochondria in the aetiology and pathogenesis of Parkinson's disease. *Lancet Neurol*. 2008; 7: 97–109.
48. **Biskup S, Gerlach M, Kupsch A, *et al.*** Genes associated with Parkinson syndrome. *J Neurol*. 2008; 255: 8–17.
49. **Devi L, Raghavendran V, Prabhu BM, *et al.*** Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. *J Biol Chem*. 2008; 283: 9089–100.
50. **Yang H, Zhou HY, Li B, *et al.*** Downregulation of parkin damages antioxidant defenses and enhances proteasome inhibition-induced toxicity in PC12 cells. *J Neuroimmune Pharmacol*. 2007; 2: 276–83.
51. **Kim Y, Park J, Kim S, *et al.*** PINK1 controls mitochondrial localization of Parkin through direct phosphorylation. *Biochem Biophys Res Commun*. 2008; 377: 975–80.
52. **Plun-Favreau H, Klupsch K, Moisoi N, *et al.*** The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated

© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd

kinase PINK1. *Nat Cell Biol*. 2007; 9: 1243–52.
53. **Andres-Mateos E, Perier C, Zhang L, *et al.*** DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. *Proc Natl Acad Sci USA*. 2007; 104: 14807–12.
54. **Biskup S, Moore DJ, Celsi F, *et al.*** Localization of LRRK2 to membranous and vesicular structures in mammalian brain. *Ann Neurol*. 2006; 60: 557–69.
55. **Davidzon G, Greene P, Mancuso M, *et al.*** Early-onset familial parkinsonism due to POLG mutations. *Ann Neurol*. 2006; 59: 859–62.
56. **Stahl WL, Swanson PD.** Biochemical abnormalities in Huntington's chorea brains. *Neurology*. 1974; 24: 813–9.
57. **Alston TA, Mela L, Bright HJ.** 3-Nitropropionate, the toxic substance of Indigofera, is a suicide inactivator of succinate dehydrogenase. *Proc Natl Acad Sci USA*. 1977; 74: 3767–71.
58. **He FS, Zhang SL, Liu LH, *et al.*** Extrapyramidal lesions induced by mildewed sugarcane poisoning, three case reports. *Chinese J Med*. 1987; 67: 395–7.
59. **Quastel JH, Wooldridge WR.** LXXXIV. Some properties of the dehydrogenating enzymes of bacteria. *Biochem J*. 1928; 22: 689–702.
60. **Gould DH, Gustine DL.** Basal ganglia degeneration, myelin alterations, and enzyme inhibition induced in mice by the plant toxin 3-nitropropanoic acid. *Neuropathol Appl Neurobiol*. 1982; 8: 377–93.
61. **Beal MF, Brouillet E, Jenkins B, *et al.*** Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. *J Neurochem*. 1993; 61: 1147–50.
62. **Beal MF, Brouillet E, Jenkins BG, *et al.*** Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. *J Neurosci*. 1993; 13: 4181–92.
63. **Orr AL, Li S, Wang CE, *et al.*** N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. *J Neurosci*. 2008; 28: 2783–92.
64. **Panov AV, Gutekunst CA, Leavitt BR, *et al.*** Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. *Nat Neurosci*. 2002; 5: 731–6.
65. **Cui L, Jeong H, Borovecki F, *et al.*** Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. *Cell*. 2006; 127: 59–69.
66. **Lucas DR, Newhouse JP.** The toxic effect of sodium L-glutamate on the inner layers of the retina. *AMA Arch Ophthalmol*. 1957; 58: 193–201.
67. **Olney JW.** Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. *Science*. 1969; 164: 719–21.
68. **Lau A, Tymianski M.** Glutamate receptors, neurotoxicity and neurodegeneration. *Pflugers Arch*. 2010; 460: 525–42.
69. **Hardingham GE, Fukunaga Y, Bading H.** Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. *Nat Neurosci*. 2002; 5: 405–14.
70. **Tovar KR, Westbrook GL.** The incorporation of NMDA receptors with a distinct subunit composition at nascent hippocampal synapses *in vitro*. *J Neurosci*. 1999; 19: 4180–8.
71. **Liu Y, Wong TP, Aarts M, *et al.*** NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both *in vitro* and *in vivo*. *J Neurosci*. 2007; 27: 2846–57.
72. **Aramori I, Nakanishi S.** Signal transduction and pharmacological characteristics of a metabotropic glutamate receptor, mGluR1, in transfected CHO cells. *Neuron*. 1992; 8: 757–65.
73. **Abe T, Sugihara H, Nawa H, *et al.*** Molecular characterization of a novel metabotropic glutamate receptor mGluR5 coupled to inositol phosphate/Ca2+ signal transduction. *J Biol Chem*. 1992; 267: 13361–8.
74. **Tanabe Y, Nomura A, Masu M, *et al.*** Signal transduction, pharmacological properties, and expression patterns of two rat metabotropic glutamate receptors, mGluR3 and mGluR4. *J Neurosci*. 1993; 13: 1372–8.
75. **Schousboe A, Waagepetersen HS.** Role of astrocytes in glutamate homeostasis: implications for excitotoxicity. *Neurotox Res*. 2005; 8: 221–5.
76. **Novelli A, Reilly JA, Lysko PG, *et al.*** Glutamate becomes neurotoxic *via* the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. *Brain Res*. 1988; 451: 205–12.
77. **Orrenius S, Zhivotovsky B, Nicotera P.** Regulation of cell death: the calcium-apoptosis link. *Nat Rev Mol Cell Biol*. 2003; 4: 552–65.
78. **Meredith GE, Totterdell S, Beales M, *et al.*** Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson's disease. *Exp Neurol*. 2009; 219: 334–40.
79. **Caudle WM, Zhang J.** Glutamate, excitotoxicity, and programmed cell death in Parkinson disease. *Exp Neurol*. 2009; 220: 230–3.
80. **Misgeld U.** Innervation of the substantia nigra. *Cell Tissue Res*. 2004; 318: 107–14.
81. **Rodriguez MC, Obeso JA, Olanow CW.** Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. *Ann Neurol*. 1998; 44: S175–88.
82. **Coyle JT, Schwarcz R.** Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. *Nature*. 1976; 263: 244–6.
83. **McGeer EG, McGeer PL.** Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids. *Nature*. 1976; 263: 517–9.
84. **Schwarcz R, Hokfelt T, Fuxe K, *et al.*** Ibotenic acid-induced neuronal degeneration: a morphological and neurochemical study. *Exp Brain Res*. 1979; 37: 199–216.
85. **Schwarcz R, Whetsell WO Jr, Mangano RM.** Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. *Science*. 1983; 219: 316–8.
86. **Beal MF, Kowall NW, Ellison DW, *et al.*** Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. *Nature*. 1986; 321: 168–71.
87. **Fonnum F, Storm-Mathisen J, Divac I.** Biochemical evidence for glutamate as neurotransmitter in corticostriatal and corticothalamic fibres in rat brain. *Neuroscience*. 1981; 6: 863–73.
88. **Smith Y, Raju DV, Pare JF, *et al.*** The thalamostriatal system: a highly specific network of the basal ganglia circuitry. *Trends Neurosci*. 2004; 27: 520–7.
89. **Landwehrmeyer GB, Standaert DG, Testa CM, *et al.*** NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. *J Neurosci*. 1995; 15: 5297–307.
90. **Zeron MM, Hansson O, Chen N, *et al.*** Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. *Neuron*. 2002; 33: 849–60.
91. **Shehadeh J, Fernandes HB, Zeron Mullins MM, *et al.*** Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic

© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd

mouse model of Huntington disease. *Neurobiol Dis*. 2006; 21: 392–403.

92. **Young AB, Greenamyre JT, Hollingsworth Z, *et al.*** NMDA receptor losses in putamen from patients with Huntington's disease. *Science*. 1988; 241: 981–3.
93. **Kuppenbender KD, Standaert DG, Feuerstein TJ, *et al.*** Expression of NMDA receptor subunit mRNAs in neurochemically identified projection and interneurons in the human striatum. *J Comp Neurol*. 2000; 419: 407–21.
94. **Milnerwood AJ, Gladding CM, Pouladi MA, *et al.*** Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. *Neuron*. 2010; 65: 178–90.
95. **Okamoto S, Pouladi MA, Talantova M, *et al.*** Balance between synaptic *versus* extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. *Nat Med*. 2009; 15: 1407–13.
96. **Chen N, Luo T, Wellington C, *et al.*** Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. *J Neurochem*. 1999; 72: 1890–8.
97. **Song C, Zhang Y, Parsons CG, *et al.*** Expression of polyglutamine-expanded huntingtin induces tyrosine phosphorylation of N-methyl-D-aspartate receptors. *J Biol Chem*. 2003; 278: 33364–9.
98. **Heng MY, Detloff PJ, Wang PL, *et al.*** *In vivo* evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease. *J Neurosci*. 2009; 29: 3200–5.
99. **Sun Y, Savanenin A, Reddy PH, *et al.*** Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors *via* post-synaptic density 95. *J Biol Chem*. 2001; 276: 24713–8.
100. **Sattler R, Xiong Z, Lu WY, *et al.*** Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. *Science*. 1999; 284: 1845–8.
101. **Hassel B, Tessler S, Faull RL, *et al.*** Glutamate uptake is reduced in prefrontal cortex in Huntington's disease. *Neurochem Res*. 2008; 33: 232–7.
102. **Cha JH, Kosinski CM, Kerner JA, *et al.*** Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. *Proc Natl Acad Sci USA*. 1998; 95: 6480–5.
103. **Tang TS, Tu H, Chan EY, *et al.*** Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. *Neuron*. 2003; 39: 227–39.
104. **Kotake Y, Iwao J.** Über das Kynurenin, ein intermediäres Stoffwechselprodukt des Tryptophans. *Z Physiol Chem*. 1931; 195: 139–47.
105. **Matsuoka Z, Yoshimatsu N.** Über eine neue Substanz, die aus Tryptophan im Tierkörper gebildet wird. *Z Physiol Chem*. 1925; 143: 206–10.
106. **Wolf H.** The effect of hormones and vitamin B6 on urinary excretion of metabolites of the kynurenine pathway. *Scand J Clin Lab Invest Suppl*. 1974; 136: 1–186.
107. **Beadle GW, Mitchell HK, Nyc JF.** Kynurenine as an Intermediate in the Formation of Nicotinic Acid from Tryptophane by Neurospora. *Proc Natl Acad Sci USA*. 1947; 33: 155–8.
108. **Liebig J.** Ueber Kynurensäure. *Justus Liebigs Ann Chem*. 1853; 86: 125–6.
109. **Jackson RW, Jackson WT.** The metabolism of tryptophan III. The availability of kynurenine in supplementing a diet deficient in tryptophane. *J Biol Chem*. 1932; 96: 697–701.
110. **Kotake Y, Nakayama Y.** Studien über den intermediären Stoffwechsel des Tryptophans. XXXIV. Über die Anthranilsäurebildung aus Kynurenin durch Organsaft. *Z Physiol Chem*. 1941; 270: 76–82.
111. **Butenandt A, Weidel W, Schlossberger H.** 3-Oxy-Kynurenin als cn^{+}-Gen-abhängiges Glied im intermediären Tryptophan-Stoffwechsel. *Z Naturf*. 1949; 4b: 242–4.
112. **Henderson LM.** Quinolinic acid excretion by the rat receiving tryptophan. *J Biol Chem*. 1949; 178: 1005–6.
113. **Henderson LM, Hirsch HM.** Quinolinic acid metabolism; urinary excretion by the rat following tryptophan and 3-hydroxyanthranilic acid administration. *J Biol Chem*. 1949; 181: 667–75.
114. **Joseph MH.** The determination of kynurenine by gas-liquid chromatography; evidence for its presence in rat brain [proceedings]. *Br J Pharmacol*. 1977; 59: 525P.
115. **Gal EM, Sherman AD.** Synthesis and metabolism of L-kynurenine in rat brain. *J Neurochem*. 1978; 30: 607–13.
116. **Joseph MH, Kadam BV.** Kynurenine: penetration to the brain, effect on brain tryptophan and 5-hydroxytryptamine metabolism and binding to plasma albumin [proceedings]. *Br J Pharmacol*. 1979; 66: 483P–4P.
117. **Gould SE.** The uptake of kynurenine, a tryptophan metabolite, into mouse brain [proceedings]. *Br J Pharmacol*. 1979; 66: 484P–5P.
118. **Fukui S, Schwarcz R, Rapoport SI, *et al.*** Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. *J Neurochem*. 1991; 56: 2007–17.
119. **Lombardi G, Moneti G, Moroni F.** Mass-fragmentographic identification and measurement of the excitotoxin quinolinic acid in the mammalian brain. *Acta Pharmacol Toxicol*. 1983; 53: 145.
120. **Zadori D, Klivenyi P, Vamos E, *et al.*** Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies. *J Neural Transm*. 2009; 116: 1403–9.
121. **Kincses ZT, Toldi J, Vecsei L.** Kynurenines, neurodegeneration and Alzheimer's disease. *J Cell Mol Med*. 2010; DOI: 10.1111/j.582–4934.2010.01123.x.
122. **Rajda C, Bergquist J, Vecsei L.** Kynurenines, redox disturbances and neurodegeneration in multiple sclerosis. *J Neural Transm Suppl*. 2007; 72: 323–9.
123. **Lapin IP.** Kynurenines as probable participants of depression. *Pharmakopsychiatr Neuropsychopharmakol*. 1973; 6: 273–9.
124. **Lapin IP.** Stimulant and convulsive effects of kynurenines injected into brain ventricles in mice. *J Neural Transm*. 1978; 42: 37–43.
125. **Han Q, Cai T, Tagle DA, *et al.*** Structure, expression, and function of kynurenine aminotransferases in human and rodent brains. *Cell Mol Life Sci*. 2010; 67: 353–68.
126. **Okuno E, Nakamura M, Schwarcz R.** Two kynurenine aminotransferases in human brain. *Brain Res*. 1991; 542: 307–12.
127. **Yu P, Li Z, Zhang L, *et al.*** Characterization of kynurenine aminotransferase III, a novel member of a phylogenetically conserved KAT family. *Gene*. 2006; 365: 111–8.
128. **Guidetti P, Amori L, Sapko MT, *et al.*** Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain. *J Neurochem*. 2007; 102: 103–11.
129. **Guillemin GJ, Kerr SJ, Smythe GA, *et al.*** Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. *J Neurochem*. 2001; 78: 842–53.
130. **Roberts RC, Du F, McCarthy KE, *et al.*** Immunocytochemical localization of kynurenine aminotransferase in the rat striatum: a light and electron microscopic study. *J Comp Neurol*. 1992; 326: 82–90.

© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd

131. **Guidetti P, Hoffman GE, Melendez-Ferro M, *et al.*** Astrocytic localization of kynurenine aminotransferase II in the rat brain visualized by immunocytochemistry. *Glia*. 2007; 55: 78–92.
132. **Battie C, Verity MA.** Presence of kynurenine hydroxylase in developing rat brain. *J Neurochem*. 1981; 36: 1308–10.
133. **Foster AC, White RJ, Schwarcz R.** Synthesis of quinolinic acid by 3-hydroxyanthranilic acid oxygenase in rat brain tissue *in vitro*. *J Neurochem*. 1986; 47: 23–30.
134. **Espey MG, Chernyshev ON, Reinhard JF Jr, *et al.*** Activated human microglia produce the excitotoxin quinolinic acid. *Neuroreport*. 1997; 8: 431–4.
135. **Perkins MN, Stone TW.** An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. *Brain Res*. 1982; 247: 184–7.
136. **Kessler M, Terramani T, Lynch G, *et al.*** A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. *J Neurochem*. 1989; 52: 1319–28.
137. **Birch PJ, Grossman CJ, Hayes AG.** Kynurenate and FG9041 have both competitive and non-competitive antagonist actions at excitatory amino acid receptors. *Eur J Pharmacol*. 1988; 151: 313–5.
138. **Prescott C, Weeks AM, Staley KJ, *et al.*** Kynurenic acid has a dual action on AMPA receptor responses. *Neurosci Lett*. 2006; 402: 108–12.
139. **Rozsa E, Robotka H, Vecsei L, *et al.*** The Janus-face kynurenic acid. *J Neural Transm*. 2008; 115: 1087–91.
140. **Hilmas C, Pereira EF, Alkondon M, *et al.*** The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. *J Neurosci*. 2001; 21: 7463–73.
141. **Marchi M, Risso F, Viola C, *et al.*** Direct evidence that release-stimulating alpha7* nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals. *J Neurochem*. 2002; 80: 1071–8.
142. **Wang J, Simonavicius N, Wu X, *et al.*** Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. *J Biol Chem*. 2006; 281: 22021–8.
143. **Csillik AE, Okuno E, Csillik B, *et al.*** Expression of kynurenine aminotransferase in the subplate of the rat and its possible role in the regulation of programmed cell death. *Cereb Cortex*. 2002; 12: 1193–201.
144. **de Carvalho LP, Bochet P, Rossier J.** The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits. *Neurochem Int*. 1996; 28: 445–52.
145. **Stone TW, Perkins MN.** Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. *Eur J Pharmacol*. 1981; 72: 411–2.
146. **Connick JH, Stone TW.** Quinolinic acid effects on amino acid release from the rat cerebral cortex *in vitro* and *in vivo*. *Br J Pharmacol*. 1988; 93: 868–76.
147. **Tavares RG, Tasca CI, Santos CE, *et al.*** Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. *Neurochem Int*. 2002; 40: 621–7.
148. **Behan WM, McDonald M, Darlington LG, *et al.*** Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl. *Br J Pharmacol*. 1999; 128: 1754–60.
149. **Rios C, Santamaria A.** Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. *Neurochem Res*. 1991; 16: 1139–43.
150. **Eastman CL, Guilarte TR.** The role of hydrogen peroxide in the *in vitro* cytotoxicity of 3-hydroxykynurenine. *Neurochem Res*. 1990; 15: 1101–7.
151. **Okuda S, Nishiyama N, Saito H, *et al.*** 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. *J Neurochem*. 1998; 70: 299–307.
152. **Dykens JA, Sullivan SG, Stern A.** Oxidative reactivity of the tryptophan metabolites 3-hydroxyanthranilate, cinnabarinate, quinolinate and picolinate. *Biochem Pharmacol*. 1987; 36: 211–7.
153. **Jhamandas K, Boegman RJ, Beninger RJ, *et al.*** Quinolinate-induced cortical cholinergic damage: modulation by tryptophan metabolites. *Brain Res*. 1990; 529: 185–91.
154. **Ogawa T, Matson WR, Beal MF, *et al.*** Kynurenine pathway abnormalities in Parkinson's disease. *Neurology*. 1992; 42: 1702–6.
155. **Knyihar-Csillik E, Csillik B, Pakaski M, *et al.*** Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment. *Neuroscience*. 2004; 126: 899–914.
156. **Knyihar-Csillik E, Chadaide Z, Mihaly A, *et al.*** Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra. *Acta Neuropathol*. 2006; 112: 127–37.
157. **Luchowski P, Luchowska E, Turski WA, *et al.*** 1-Methyl-4-phenylpyridinium and 3-nitropropionic acid diminish cortical synthesis of kynurenic acid *via* interference with kynurenine aminotransferases in rats. *Neurosci Lett*. 2002; 330: 49–52.
158. **Beal MF, Matson WR, Swartz KJ, *et al.*** Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid. *J Neurochem*. 1990; 55: 1327–39.
159. **Jauch D, Urbanska EM, Guidetti P, *et al.*** Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases. *J Neurol Sci*. 1995; 130: 39–47.
160. **Guidetti P, Luthi-Carter RE, Augood SJ, *et al.*** Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. *Neurobiol Dis*. 2004; 17: 455–61.
161. **Heyes MP, Saito K, Crowley JS, *et al.*** Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. *Brain*. 1992; 115: 1249–73.
162. **Schwarcz R, Okuno E, White RJ, *et al.*** 3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims. *Proc Natl Acad Sci USA*. 1988; 85: 4079–81.
163. **Vecsei L, Beal MF.** Comparative behavioral and neurochemical studies with striatal kainic acid- or quinolinic acid-lesioned rats. *Pharmacol Biochem Behav*. 1991; 39: 473–8.
164. **Schwarcz R, Guidetti P, Sathyasaikumar KV, *et al.*** Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease. *Prog Neurobiol*. 2010; 90: 230–45.
165. **Sapko MT, Guidetti P, Yu P, *et al.*** Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease. *Exp Neurol*. 2006; 197: 31–40.
166. **Pearson SJ, Reynolds GP.** Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease. *Neurosci Lett*. 1992; 144: 199–201.
167. **Guidetti P, Schwarcz R.** 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum. *Eur J Neurosci*. 1999; 11: 3857–63.

© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd

168. **Csillik A, Knyihar E, Okuno E, *et al.*** Effect of 3-nitropropionic acid on kynurenine aminotransferase in the rat brain. *Exp Neurol*. 2002; 177: 233–41.
169. **Giorgini F, Guidetti P, Nguyen Q, *et al.*** A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. *Nat Genet*. 2005; 37: 526–31.
170. **Hersch SM, Rosas HD.** Neuroprotection for Huntington's disease: ready, set, slow. *Neurotherapeutics*. 2008; 5: 226–36.
171. **Klivenyi P, Vecsei L.** Novel therapeutic strategies in Parkinson's disease. *Eur J Clin Pharmacol*. 2010; 66: 119–25.
172. **Zuccato C, Valenza M, Cattaneo E.** Molecular mechanisms and potential therapeutical targets in Huntington's disease. *Physiol Rev*. 2010; 90: 905–81.
173. **Kincses ZT, Vecsei L.** Pharmacological therapy in Parkinson's disease: focus on neuroprotection. *CNS Neurosci Ther*. 2010; DOI: 10.1111/j.755–5949.2010.00150.x.
174. **Liu J, Atamna H, Kuratsune H, *et al.*** Delaying brain mitochondrial decay and aging with mitochondrial antioxidants and metabolites. *Ann NY Acad Sci*. 2002; 959: 133–66.
175. **Wang C, Sadovova N, Ali HK, *et al.*** L-carnitine protects neurons from 1-methyl-4-phenylpyridinium-induced neuronal apoptosis in rat forebrain culture. *Neuroscience*. 2007; 144: 46–55.
176. **Bodis-Wollner I, Chung E, Ghilardi MF, *et al.*** Acetyl-levo-carnitine protects against MPTP-induced parkinsonism in primates. *J Neural Transm Park Dis Dement Sect*. 1991; 3: 63–72.
177. **Zhang H, Jia H, Liu J, *et al.*** Combined R-alpha-lipoic acid and acetyl-L-carnitine exerts efficient preventative effects in a cellular model of Parkinson's disease. *J Cell Mol Med*. 2010; 14: 215–25.
178. **Nishimura M, Okimura Y, Fujita H, *et al.*** Mechanism of 3-nitropropionic acid-induced membrane permeability transition of isolated mitochondria and its suppression by L-carnitine. *Cell Biochem Funct*. 2008; 26: 881–91.
179. **Vamos E, Voros K, Vecsei L, *et al.*** Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease. *Biomed Pharmacother*. 2010; 64: 282–6.
180. **Goetz CG, Tanner CM, Cohen JA, *et al.*** L-acetyl-carnitine in Huntington's disease: double-blind placebo controlled crossover study of drug effects on movement disorder and dementia. *Mov Disord*. 1990; 5: 263–5.
181. **Boldyrev AA, Stvolinsky SL, Fedorova TN, *et al.*** Carnosine as a natural antioxidant and geroprotector: from molecular mechanisms to clinical trials. *Rejuvenation Res*. 2010; 13: 156–8.
182. **Boldyrev A, Fedorova T, Stepanova M, *et al.*** Carnosine increases efficiency of DOPA therapy of Parkinson's disease: a pilot study. *Rejuvenation Res*. 2008; 11: 821–7.
183. **Beal MF, Matthews RT, Tieleman A, *et al.*** Coenzyme Q_{10} attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. *Brain Res*. 1998; 783: 109–14.
184. **Schilling G, Coonfield ML, Ross CA, *et al.*** Coenzyme Q_{10} and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. *Neurosci Lett*. 2001; 315: 149–53.
185. **Ferrante RJ, Andreassen OA, Dedeoglu A, *et al.*** Therapeutic effects of coenzyme Q_{10} and remacemide in transgenic mouse models of Huntington's disease. *J Neurosci*. 2002; 22: 1592–9.
186. **Strijks E, Kremer HP, Horstink MW.** Q10 therapy in patients with idiopathic Parkinson's disease. *Mol Aspects Med*. 1997; 18: S237–40.
187. **Shults CW, Oakes D, Kieburtz K, *et al.*** Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. *Arch Neurol*. 2002; 59: 1541–50.
188. **Muller T, Buttner T, Gholipour AF, *et al.*** Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. *Neurosci Lett*. 2003; 341: 201–4.
189. **Storch A, Jost WH, Vieregge P, *et al.*** Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. *Arch Neurol*. 2007; 64: 938–44.
190. **Huntington Study Group.** A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. *Neurology*. 2001; 57: 397–404.
191. **The Huntington Study Group Pre2CARE Investigators.** Safety and tolerability of high-dosage coenzyme Q(10) in Huntington's disease and healthy subjects. *Mov Disord*. 2010; 25: 1924–8.
192. **Hemmer W, Wallimann T.** Functional aspects of creatine kinase in brain. *Dev Neurosci*. 1993; 15: 249–60.
193. **O'Gorman E, Beutner G, Dolder M, *et al.*** The role of creatine kinase in inhibition of mitochondrial permeability transition. *FEBS Lett*. 1997; 414: 253–7.
194. **Matthews RT, Ferrante RJ, Klivenyi P, *et al.*** Creatine and cyclocreatine attenuate MPTP neurotoxicity. *Exp Neurol*. 1999; 157: 142–9.
195. **Matthews RT, Yang L, Jenkins BG, *et al.*** Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. *J Neurosci*. 1998; 18: 156–63.
196. **Ferrante RJ, Andreassen OA, Jenkins BG, *et al.*** Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. *J Neurosci*. 2000; 20: 4389–97.
197. **Andreassen OA, Dedeoglu A, Ferrante RJ, *et al.*** Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. *Neurobiol Dis*. 2001; 8: 479–91.
198. **NINDS NET-PD Investigators.** A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. *Neurology*. 2006; 66: 664–71.
199. **NINDS NET-PD Investigators.** A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. *Clin Neuropharmacol*. 2008; 31: 141–50.
200. **Bender A, Koch W, Elstner M, *et al.*** Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. *Neurology*. 2006; 67: 1262–4.
201. **Tabrizi SJ, Blamire AM, Manners DN, *et al.*** Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study. *Neurology*. 2003; 61: 141–2.
202. **Tabrizi SJ, Blamire AM, Manners DN, *et al.*** High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study. *Neurology*. 2005; 64: 1655–6.
203. **Verbessem P, Lemiere J, Eijnde BO, *et al.*** Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial. *Neurology*. 2003; 61: 925–30.
204. **Kessler A, Biasibetti M, da Silva Melo DA, *et al.*** Antioxidant effect of cysteamine in brain cortex of young rats. *Neurochem Res*. 2008; 33: 737–44.
205. **Rech VC, Feksa LR, Fleck RM, *et al.*** Cysteamine prevents inhibition of thiol-containing enzymes caused by cystine or cystine dimethylester loading in rat brain cortex. *Metab Brain Dis*. 2008; 23: 133–45.
206. **Karpuj MV, Becher MW, Steinman L.** Evidence for a role for transglutaminase in

© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd

Huntington's disease and the potential therapeutic implications. *Neurochem Int*. 2002; 40: 31–6.

207. **Martinovits G, Melamed E, Cohen O, *et al.*** Systemic administration of antioxidants does not protect mice against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP). *Neurosci Lett*. 1986; 69: 192–7.
208. **Sun L, Xu S, Zhou M, *et al.*** Effects of cysteamine on MPTP-induced dopaminergic neurodegeneration in mice. *Brain Res*. 2010; 1335: 74–82.
209. **Tremblay ME, Saint-Pierre M, Bourhis E, *et al.*** Neuroprotective effects of cystamine in aged parkinsonian mice. *Neurobiol Aging*. 2006; 27: 862–70.
210. **Karpuj MV, Becher MW, Springer JE, *et al.*** Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. *Nat Med*. 2002; 8: 143–9.
211. **Dedeoglu A, Kubilus JK, Jeitner TM, *et al.*** Therapeutic effects of cystamine in a murine model of Huntington's disease. *J Neurosci*. 2002; 22: 8942–50.
212. **Van Raamsdonk JM, Pearson J, Bailey CD, *et al.*** Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. *J Neurochem*. 2005; 95: 210–20.
213. **Dubinsky R, Gray C.** CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease. *Mov Disord*. 2006; 21: 530–3.
214. **Jump DB.** The biochemistry of n-3 polyunsaturated fatty acids. *J Biol Chem*. 2002; 277: 8755–8.
215. **Vaddadi KS.** Essential fatty acids and movement disorders. In: Peet M, Glen I, Horrobin DF, editors. Phospholipid spectrum disorders in psychiatry. Carnforth: Marius Press; 1999. pp. 285–96.
216. **Clifford JJ, Drago J, Natoli AL, *et al.*** Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease. *Neuroscience*. 2002; 109: 81–8.
217. **Vaddadi KS, Soosai E, Chiu E, *et al.*** A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids. *Neuroreport*. 2002; 13: 29–33.
218. **Van Raamsdonk JM, Pearson J, Rogers DA, *et al.*** Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. *Exp Neurol*. 2005; 196: 266–72.
219. **Puri BK, Bydder GM, Counsell SJ, *et al.*** MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. *Neuroreport*. 2002; 13: 123–6.
220. **Puri BK, Bydder GM, Manku MS, *et al.*** Reduction in cerebral atrophy associated with ethyl-eicosapentaenoic acid treatment in patients with Huntington's disease. *J Int Med Res*. 2008; 36: 896–905.
221. **Puri BK, Leavitt BR, Hayden MR, *et al.*** Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. *Neurology*. 2005; 65: 286–92.
222. **Huntington Study Group TREND-HD Investigators.** Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. *Arch Neurol*. 2008; 65: 1582–9.
223. **Andreassen OA, Ferrante RJ, Dedeoglu A, *et al.*** Lipoic acid improves survival in transgenic mouse models of Huntington's disease. *Neuroreport*. 2001; 12: 3371–3.
224. **Mazzio E, Soliman KF.** Pyruvic acid cytoprotection against 1-methyl-4-phenylpyridinium, 6-hydroxydopamine and hydrogen peroxide toxicities *in vitro*. *Neurosci Lett*. 2003; 337: 77–80.
225. **Choi JS, Lee MS, Jeong JW.** Ethyl pyruvate has a neuroprotective effect through activation of extracellular signal-regulated kinase in Parkinson's disease model. *Biochem Biophys Res Commun*. 2010; 394: 854–8.
226. **Ryu JK, Kim SU, McLarnon JG.** Neuroprotective effects of pyruvate in the quinolinic acid rat model of Huntington's disease. *Exp Neurol*. 2003; 183: 700–4.
227. **Wu G.** Amino acids: metabolism, functions, and nutrition. *Amino Acids*. 2009; 37: 1–17.
228. **Tadros MG, Khalifa AE, Abdel-Naim AB, *et al.*** Neuroprotective effect of taurine in 3-nitropropionic acid-induced experimental animal model of Huntington's disease phenotype. *Pharmacol Biochem Behav*. 2005; 82: 574–82.
229. **Perry TL, Yong VW, Hansen S, *et al.*** Alpha-tocopherol and beta-carotene do not protect marmosets against the dopaminergic neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. *J Neurol Sci*. 1987; 81: 321–31.
230. **The Parkinson Study Group.** Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. *N Engl J Med*. 1993; 328: 176–83.
231. **Cadet JL, Katz M, Jackson-Lewis V, *et al.*** Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence. *Brain Res*. 1989; 476: 10–5.
232. **Bostanci MO, Bas O, Bagirici F.** Alpha-tocopherol decreases iron-induced hippocampal and nigral neuron loss. *Cell Mol Neurobiol*. 2010; 30: 389–94.
233. **Fahn S.** A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease. *Ann Neurol*. 1992; 32: S128–32.
234. **Peyser CE, Folstein M, Chase GA, *et al.*** Trial of d-alpha-tocopherol in Huntington's disease. *Am J Psychiatry*. 1995; 152: 1771–5.
235. **Itoh N, Masuo Y, Yoshida Y, *et al.*** gamma-Tocopherol attenuates MPTP-induced dopamine loss more efficiently than alpha-tocopherol in mouse brain. *Neurosci Lett*. 2006; 403: 136–40.
236. **Miranda AF, Boegman RJ, Beninger RJ, *et al.*** Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid. *Neuroscience*. 1997; 78: 967–75.
237. **Harris CA, Miranda AF, Tanguay JJ, *et al.*** Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid. *Br J Pharmacol*. 1998; 124: 391–9.
238. **Nozaki K, Beal MF.** Neuroprotective effects of L-kynurenine on hypoxia-ischemia and NMDA lesions in neonatal rats. *J Cereb Blood Flow Metab*. 1992; 12: 400–7.
239. **Gigler G, Szenasi G, Simo A, *et al.*** Neuroprotective effect of L-kynurenine sulfate administered before focal cerebral ischemia in mice and global cerebral ischemia in gerbils. *Eur J Pharmacol*. 2007; 564: 116–22.
240. **Knyihar-Csillik E, Toldi J, Mihaly A, *et al.*** Kynurenine in combination with probenecid mitigates the stimulation-induced increase of c-fos immunoreactivity of the rat caudal trigeminal nucleus in an experimental migraine model. *J Neural Transm*. 2007; 114: 417–21.
241. **Vamos E, Pardutz A, Fejes A, *et al.*** Modulatory effects of probenecid on the nitroglycerin-induced changes in the rat caudal trigeminal nucleus. *Eur J Pharmacol*. 2009; 621: 33–7.
242. **Vamos E, Voros K, Zadori D, *et al.*** Neuroprotective effects of probenecid in a transgenic animal model of Huntington's disease. *J Neural Transm*. 2009; 116: 1079–86.
243. **Graham WC, Robertson RG, Sambrook MA, *et al.*** Injection of excitatory amino

© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd

acid antagonists into the medial pallidal segment of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated primate reverses motor symptoms of parkinsonism. *Life Sci*. 1990; 47: PL91–7.

244. **Butler EG, Bourke DW, Finkelstein DI, *et al.*** The effects of reversible inactivation of the subthalamo-pallidal pathway on the behaviour of naive and hemiparkinsonian monkeys. *J Clin Neurosci*. 1997; 4: 218–27.
245. **Bahn A, Ljubojevic M, Lorenz H, *et al.*** Murine renal organic anion transporters mOAT1 and mOAT3 facilitate the transport of neuroactive tryptophan metabolites. *Am J Physiol Cell Physiol*. 2005; 289: C1075–84.
246. **Stone TW.** Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. *Trends Pharmacol Sci*. 2000; 21: 149–54.
247. **Schwarcz R.** The kynurenine pathway of tryptophan degradation as a drug target. *Curr Opin Pharmacol*. 2004; 4: 12–7.
248. **Fulop F, Szatmari I, Vamos E, *et al.*** Syntheses, transformations and pharmaceutical applications of kynurenic acid derivatives. *Curr Med Chem*. 2009; 16: 4828–42.
249. **Merino M, Vizuete ML, Cano J, *et al.*** The non-NMDA glutamate receptor antagonists 6-cyano-7-nitroquinoxaline-2, 3-dione and 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline, but not NMDA antagonists, block the intrastriatal neurotoxic effect of MPP+. *J Neurochem*. 1999; 73: 750–7.
250. **Guidetti P, Wu HQ, Schwarcz R.** In situ produced 7-chlorokynurenate provides protection against quinolinate- and malonate-induced neurotoxicity in the rat striatum. *Exp Neurol*. 2000; 163: 123–30.
251. **Parli CJ, Krieter P, Schmidt B.** Metabolism of 6-chlorotryptophan to 4-chloro-3-hydroxyanthranilic acid: a potent inhibitor of 3-hydroxyanthranilic acid oxidase. *Arch Biochem Biophys*. 1980; 203: 161–6.
252. **Leeson PD, Baker R, Carling RW, *et al.*** Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor. *J Med Chem*. 1991; 34: 1243–52.
253. **Borza I, Kolok S, Galgoczy K, *et al.*** Kynurenic acid amides as novel NR2B selective NMDA receptor antagonists. *Bioorg Med Chem Lett*. 2007; 17: 406–9.
254. **Vamos E, Fejes A, Koch J, *et al.*** Kynurenate derivative attenuates the nitroglycerin-induced CamKIIalpha and CGRP expression changes. *Headache*. 2010; 50: 834–43.
255. **Marosi M, Nagy D, Farkas T, *et al.*** A novel kynurenic acid analogue: a comparison with kynurenic acid. An *in vitro* electrophysiological study. *J Neural Transm*. 2010; 117: 183–8.
256. **Zadori D, Nyiri G, Szonyi A, *et al.*** Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease. *J Neural Transm*. 2011; DOI: 10.1007/s00702-010-0573-6.

© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd